ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 844

Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Follow-up in a US Observational Study

Kenneth G. Saag1, Kevin L. Winthrop2, Daniel E. Furst3, Kimberly Alexander4, Angelika Jahreis5, Carol Chung6 and Kurt Oelke7, 1Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 2Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 3University of California at Los Angeles, Los Angeles, CA, 4Epidemiology, Genentech, Inc., South San Francisco, CA, 5Genentech, South San Francisco, CA, 6Genentech, Inc, South San Francisco, CA, 7Rheumatic Disease Center, Glendale, WI

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Infection, registry, rheumatoid arthritis (RA) and rituximab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy I: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Malignancy and Infection

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rituximab (RTX) is an approved treatment for rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti–TNF therapy (aTNF-IR). Long-term infection risk data of RTX use in real-world settings are limited. The objective of this study was to describe the frequency of significant infections in pts with RA initiating RTX in the US.

Methods: SUNSTONE was a prospective observational cohort study designed to evaluate the safety of RTX in TNF-IR RA pts in a real-world setting. Pts were evaluated and treated according to their physicians‘ standard practices and followed at visits every 6 months. Pts were followed for 5 years (regardless of RTX discontinuation or start of another biologic DMARD), until death, withdrawal of consent or loss to follow-up. Significant infections were defined as infections that meet FDA serious AE criteria or require IV antibiotics. For calculation of incidence rates (IRs), pts were censored at the time of first event, switch to another biologic DMARD, death, withdrawal of consent or loss to follow-up. IRs by year after RTX initiation and by RTX course are described. Course was defined as 2 × 1000-mg infusions separated by ≤21 days. Pts not treated according to this regimen were excluded from the course analysis. Among pts who switched to another biologic DMARD during follow-up, the IRs of significant infection before and after switch were also calculated. IR calculations after switch were censored at the time of first event, death, withdrawal of consent or loss to follow-up. IRs per 100 pt-yrs (PY) are reported.

Results: Overall, 938 pts (3778 PY) received RTX (82% F; median age, 58 y; median disease duration, 9 y; 72% RF+). Mean duration of follow-up was 4 y and mean number of RTX courses was 4; however, not all pts were treated following the labeled dose regimen. Four pts with insufficient information to calculate IRs were excluded. Significant infections were reported in 160 pts (17%), with an IR of 6.4 (95% CI, 5.5 to 7.4). IRs in 1-y increments following RTX initiation were 7.1 (95%CI: 5.5-9.2), 6.5 (95%CI: 4.8-8.7), 8.0 (95%CI: 5.9-10.9), 9.2 (95%CI: 6.6-12.7) and 7.0 (95%CI:4.7-10.3) in years 0-1, 1-2, 2-3, 3-4, and 4-5, respectively. See table for IR and 95%CI by course; exposure is less than 100PY from Course 7 onward resulting in wide 95%CIs around IR estimates. Among 338 pts who switched to another biologic DMARD, IRs before and after switch were 4.6 (95% CI, 3.1 to 6.7) and 4.5 (95% CI, 3.3 to 6.2), respectively.

Conclusion : Data from SUNSTONE with up to 5 years of follow-up showed that risk of significant infection among pts with refractory RA that were treated with RTX after an inadequate response to an aTNF agent did not increase over time and with multiple courses. In addition, switch from RTX to another biologic DMARD was not associated with an increased risk of significant infection.

 

Course 1

N = 859;

PY = 676

Course 2

N = 558;

PY = 459

Course 3

N = 378;

PY = 282

Course 4

N = 281;

PY = 186

Course 5

N = 212;

PY = 143

Course 6

N = 158;

PY = 100

Course 7

N = 115;

PY = 73

Course 8

N = 83;

PY = 46

Course 9

N = 57;

PY = 28

IR/100 PY

7.4

6.1

7.1

4.8

7.7

6.0

1.4

2.2

7.2

95% CI

5.6-9.8

4.2-8.8

4.6-11.0

2.5-9.3

4.3-13.9

2.7-13.4

0.2-9.7

0.3-15.4

1.8-28.8

 


Disclosure:

K. G. Saag,

Amgen,

2,

Merck Pharmaceuticals,

2,

Takeda,

2,

Ardea,

2,

Abbott Immunology Pharmaceuticals,

5,

AbbVie,

5,

Amgen,

5,

Ardea,

5,

BioCryst,

5,

Bristol-Myers Squibb,

5,

Eli Lilly and Company,

5,

Crescendo,

5,

Iroko,

5,

Merck Pharmaceuticals,

5,

Roche Pharmaceuticals,

5,

NOV VP Board of Trustees,

6,

ACR Board of Directors,

6;

K. L. Winthrop,

Pfizer Inc,

2,

Pfizer, UCB, AbbVie, Genentech,

5;

D. E. Furst,

AbbVie, Actelion, Amgen, BMS, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB,

2,

AbbVie, Actelion, Amgen, BMS, Cytori, Janssen, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB,

5,

AbbVie, Actelion, UCB ,

8;

K. Alexander,

Genentech, Inc,

3;

A. Jahreis,

Genentech and Biogen IDEC Inc.,

3;

C. Chung,

Genentech, Inc,

3;

K. Oelke,

Abbvie, Amgen, GSK, crescendo biosciences, Pfizer, UCB, BMS,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-of-significant-infection-in-patients-with-ra-following-initiation-of-rituximab-with-up-to-5-years-of-follow-up-in-a-us-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology